Who makes ASF 1096 0.5 % cream applied twice daily?

ASF 1096 0.5 % cream applied twice daily is developed by Astion Pharma A/S.

What development phase is ASF 1096 0.5 % cream applied twice daily in?

ASF 1096 0.5 % cream applied twice daily is in Phase 2.

Last reviewed 2026-04-23 · How we verify

ASF 1096 0.5 % cream applied twice daily

Astion Pharma A/S · Phase 2 active Small molecule

ASF 1096 is a topical cream formulation with an unknown mechanism of action in Phase 2 development by Astion Pharma A/S.

At a glance

Generic name	ASF 1096 0.5 % cream applied twice daily
Sponsor	Astion Pharma A/S
Modality	Small molecule
Therapeutic area	Dermatology
Phase	Phase 2

Mechanism of action

Without publicly available information on ASF 1096's molecular target or mechanism, the specific pharmacological action cannot be determined. As a 0.5% cream applied topically twice daily, it is designed for dermatological application, but the active ingredient's mechanism remains proprietary or undisclosed in available literature.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ASF 1096 0.5 % cream applied twice daily CI brief — competitive landscape report
ASF 1096 0.5 % cream applied twice daily updates RSS · CI watch RSS
Astion Pharma A/S portfolio CI